GlassScriptPhysician profile
Ryan D Owens
NPI 1306211677
$3,699.05
in general payments reported to CMS, 2019-2025
30 companies · $834 in 2025
The $834 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $847 · 2022: $666 · 2023: $782 · 2024: $570 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,185.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $389.15 | 2022-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $384.76 | 2022-2025 | Lifevest |
| Preventric Diagnostics, INC. | $384.19 | 2021 | |
| Boston Scientific Corporation | $292.93 | 2023-2025 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $240.47 | 2021-2023 | Eliquis, Camzyos |
| Actelion Pharmaceuticals US, INC. | $225.29 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Inspire Medical Systems, INC. | $192.55 | 2023-2025 | Inspire |
| Merck Sharp & Dohme LLC | $183.74 | 2023-2025 | Verquvo |
| Astellas Pharma US INC | $174.94 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $158.56 | 2022-2025 | Dupixent, Evkeeza |
| Genzyme Corporation | $133.10 | 2023-2025 | |
| Stryker Corporation | $111.22 | 2021-2025 | Xpress Loprofile, Clarifix |
| Smith+Nephew, INC. | $108.95 | 2023-2024 | Tula |
| Glaxosmithkline, LLC. | $104.84 | 2024-2025 | Nucala |
| Esperion Therapeutics, INC. | $104.76 | 2021-2024 | Nexletol |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $82.72 | 2022 | |
| Amgen INC. | $70.24 | 2021-2025 | Repatha |
| Abbvie INC. | $56.07 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $54.75 | 2025 | Tezspire, Farxiga |
| Amarin Pharma, INC. | $43.56 | 2021-2022 | |
| Novo Nordisk INC | $36.53 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $26.77 | 2022 | |
| Welch Allyn | $24.38 | 2021 | |
| Scpharmaceuticals INC. | $20.05 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.32 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.88 | 2025 | Nuzyra, Xhance |
| Azurity Pharmaceuticals, INC. | $16.53 | 2023 | Edarbi |
| Intersect Ent, INC. | $13.99 | 2022 | |
| Abbott Laboratories | $13.79 | 2023 | Infinity |
| Bayer Healthcare Pharmaceuticals INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.